Showing 1 - 20 results of 26 for search 'Jae-Cheol Jo', query time: 0.08s
Refine Results
-
1
PB2298: CHRONIC HEPATITIS B VIRAL ACTIVITY IS AN INDEPENDENT PROGNOSTIC FACTOR OF LYMPHOMA by Ho Sup Lee, Jae-Cheol Jo, Da-Jung Kim
Published 2023-08-01
Article -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act by Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
Published 2021-04-01
Article -
10
-
11
-
12
-
13
The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation by Sook-Kyoung Heo, Eui-Kyu Noh, Yoo Jin Lee, Yerang Shin, Youjin Kim, Hyeon-Su Im, Hyeyeong Kim, Su Jin Koh, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi
Published 2022-09-01
Article -
14
Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study by Yunsuk Choi, Jung-Hee Lee, Chul Won Jung, Jae-Cheol Jo, Jin Seok Kim, Inho Kim, Silvia Park, June-won Cheong, Sang-Hyuk Park, Sung-Yong Kim, Hong-Ghi Lee
Published 2021-01-01
Article -
15
-
16
LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells. by Sook-Kyoung Heo, Yunsuk Choi, Yoo Kyung Jeong, Lan Jeong Ju, Ho-Min Yu, Do Kyoung Kim, Hye Jin Seo, Yoo Jin Lee, Jaekyung Cheon, SuJin Koh, Young Joo Min, Eui-Kyu Noh, Jae-Cheol Jo
Published 2021-01-01
Article -
17
Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy by In Hee Lee, Byung Woog Kang, Jong Gwang Kim, Woo Kyun Bae, Myung Seo Ki, Inkeun Park, Jae-Cheol Jo, Jin Young Kim, Sung Ae Koh, Kyung Hee Lee, Yoon Young Cho, Hun Mo Ryoo, Sang Gyu Kwak, Jung Lim Lee, Sun Ah Lee
Published 2020-01-01
Article -
18
P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 DREAMM... by Natalie Callander, Paul Richardson, Marek Hus, Vincent Ribrag, Joaquín Martinez-Lopez, Kihyun Kim, Jae Hoon Lee, Meletios A. Dimopoulos, Fredrik Schjesvold, Thierry Facon, Jae-Cheol Jo, Chang-Ki Min, Michał Mielnik, Shinta Cheng, Mary Smith, Caroline J. Breitbach, Chris Brawley, Harjeet Sembhi, John Lamacchia, Sebastian Grosicki
Published 2023-08-01
Article -
19
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma by Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Published 2023-07-01
Article -
20
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma by Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Published 2023-03-01
Article